Prudential Financial Inc Oncocyte Corp Transaction History

Prudential Financial Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $12,388 - $22,039	-14,405 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.15 - $2.25 $95,679 - $187,200	-83,200 Reduced 85.24%	14,405 $21,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $96,073 - $169,071	47,095 Added 93.24%	97,605 $212,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $178,300 - $297,503	50,510 New	50,510 $180,000
Q1 2021 May 12, 2021	SELL	$2.39 - $6.5 $37,217 - $101,218	-15,572 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.2 - $1.89 $18,686 - $29,431	15,572 New	15,572 $22,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.